Recently, a journalist and author from New York contacted me about a book he’s working on. His theme is the role that humor plays in helping people cope with a wide variety of diseases, disabilities, and physical conditions. He wanted to include my ALS-related experiences, and I gladly agreed to…
A Sense of Humor Is Vital to Living With ALS
An abnormal version of tau, a protein associated with Alzheimer’s disease, may contribute to the progression of amyotrophic lateral sclerosis (ALS) by damaging mitochondria in neurons, according to a new study. The findings suggest that decreasing tau levels might be a new therapeutic strategy to lessen mitochondrial dysfunction in…
BioArctic AB announced that it is advancing work into selective antibodies against TAR DNA-binding protein 43 (TDP-43) that when misfolded can form the toxic clumps, or aggregates, believed to be involved in the development of amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. One potential therapy approach is called…
Prilenia Therapeutics has raised $43 million to support potential regulatory submissions and marketing of its lead candidate, pridopidine, for the treatment of amyotrophic lateral sclerosis (ALS). The funding, obtained through a Series B financing round, also will be used to support the potential marketing of the candidate therapy for…
I’ve been preparing for winter. I drained the hoses and hung them in the garage a few weeks ago. We used the lawnmower to pull Comet’s doghouse from our backyard to the front porch, where he will still be able to get into it after the snow accumulates. I called…
Recent findings and ongoing efforts to more fully understand the underlying molecular mechanisms of amyotrophic lateral sclerosis (ALS), and to identify new and better ways of helping patients were discussed at the 11th Annual Les Turner Symposium on ALS. The daylong event, held virtually Nov. 1, was sponsored by the …
“All our times have come Here but now they’re gone Seasons don’t fear the reaper Nor do the wind, the sun, or the rain We can be like they are.” I was 18 years old when the band Blue Oyster Cult released the song “(Don’t Fear) The Reaper.” Coinciding…
Once a first-round draft pick for the Atlanta Falcons, Tim Green now is battling another opponent — amyotrophic lateral sclerosis (ALS). The disease has left him unable to walk, speak, eat, drink, or breathe on his own, but he hasn’t let it obscure his positive outlook on life. “I…
The HEALEY ALS platform trial, the first study to test several therapy candidates for amyotrophic lateral sclerosis (ALS) simultaneously, has completed enrollment for at least two of its first three regimens. These include Clene Nanomedicine’s CNM-Au8 (NCT04414345) and Biohaven Pharmaceuticals’ verdiperstat (NCT04436510). The recruitment status…
A first patient has been enrolled in a Phase 3 clinical trial investigating FNP122, an oral formulation of edaravone being developed by Ferrer to treat amyotrophic lateral sclerosis (ALS). The ADORE trial aims to enroll 300 patients across Europe to assess the safety and efficacy of FNP122, as well as its…
Recent Posts
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients
- Scientists grow specialized motor neurons to aid in ALS research